• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study.

作者信息

Verhoeven W M, Tuinier S

机构信息

Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands.

出版信息

J Intellect Disabil Res. 1996 Dec;40 ( Pt 6):502-8.

PMID:9004110
Abstract

During the past few decades, suggestive evidence has been accumulated that abnormalities in serotonin neurotransmission are involved in the pathogenesis of aggressive behaviour disorders and impulsivity. Support for this idea can be derived from clinical studies using 5-HT1 agonistic compounds and serotonergic antidepressants. In the present study, the efficacy of the 5-HT1a agonist buspirone was investigated in eight patients with mental retardation and severe, long-lasting challenging behaviour, characterized by aggressive outbursts, self-injurious behaviour and impulsivity. The findings demonstrate that buspirone, in a daily dosage varying between 20 and 50 mg, may be effective in reducing this type of behavioural disturbance and associated with an improvement in sociability. It is hypothesized that the responsiveness to buspirone treatment may be the result of a de-arousing phenomenon, mediated via corticosteroid dependent stress homeostatic mechanisms.

摘要

相似文献

1
The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study.
J Intellect Disabil Res. 1996 Dec;40 ( Pt 6):502-8.
2
Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study.
J Clin Psychiatry. 1991 Apr;52(4):159-62.
3
Eltoprazine in aggressive mentally handicapped patients: a double-blind, placebo- and baseline-controlled multi-centre study. The Eltoprazine Aggression Research Group.艾托拉嗪用于攻击性智力障碍患者:一项双盲、安慰剂及基线对照的多中心研究。艾托拉嗪攻击行为研究组
Int Clin Psychopharmacol. 1994 Sep;9(3):187-94.
4
Buspirone for autistic disorder in a woman with an intellectual disability.
Ann Pharmacother. 2008 Jan;42(1):131-7. doi: 10.1345/aph.1K427. Epub 2007 Dec 4.
5
Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study.5-羟色胺1A受体激动剂盐酸丁螺环酮对伴有焦虑的偏头痛患者的疗效:一项随机、前瞻性、平行组、双盲、安慰剂对照研究。
Headache. 2005 Sep;45(8):1004-11. doi: 10.1111/j.1526-4610.2005.05181.x.
6
Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.阿奈螺酮在定居者-入侵者试验中的选择性抗攻击作用通过5-羟色胺1A受体介导:与8-羟基-2-二丙基氨基四氢萘、伊沙匹隆、丁螺环酮、依他普嗪和WAY-100635的比较药理学研究
J Pharmacol Exp Ther. 1999 Mar;288(3):1125-33.
7
Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons.
J Clin Psychiatry. 1989 Oct;50(10):382-4.
8
5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.5-羟色胺1A受体激动剂丁螺环酮和吉哌隆可减轻阿扑吗啡诱导的成年雄性Wistar大鼠的攻击行为。
J Physiol Pharmacol. 2000 Dec;51(4 Pt 2):833-46.
9
Clinical effects of buspirone on intractable self-injury in adults with mental retardation.
J Am Acad Child Adolesc Psychiatry. 1994 Feb;33(2):270-6. doi: 10.1097/00004583-199402000-00017.
10
5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.5-羟色胺1A和5-羟色胺1B受体激动剂与攻击性:血清素缺乏假说的药理学挑战
Eur J Pharmacol. 2005 Dec 5;526(1-3):125-39. doi: 10.1016/j.ejphar.2005.09.065. Epub 2005 Nov 28.

引用本文的文献

1
Neuropsychiatry of aggression.攻击性的神经精神医学
Neurol Clin. 2011 Feb;29(1):49-64, vii. doi: 10.1016/j.ncl.2010.10.006.